Products
Pre-made Burosumab benchmark antibody ( Whole mAb, anti-FGF23 therapeutic antibody, Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-086
Pre-Made Burosumab biosimilar, Whole mAb, Anti-FGF23 Antibody: Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Burosumab (INN, sold under the brand name Crysvita) is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.[ Burosumab was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018.[8] The FDA approval fell under both the breakthrough therapy and orphan drug designations. It was approved for use in the European Union in February 2018.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-086-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Burosumab biosimilar, Whole mAb, Anti-FGF23 Antibody: Anti-ADHR/FGFN/HFTC2/HPDR2/HYPF/PHPTC therapeutic antibody |
| INN Name | Burosumab |
| Target | FGF23 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Kyowa Hakko Kirin;Ultragenyx Pharmaceutical |
| Conditions Approved | X-linked dominant hypophosphataemic rickets;Osteomalacia |
| Conditions Active | Nevus |
| Conditions Discontinued | na |
| Development Tech | na |
